TCON reports 4Q16 results: http://finance.yahoo.com/news/tracon-pharmaceuticals-reports-fourth-quarter-210500086.html The 12/31/16 cash balance of $44.4M; the $8B in debt; and the 16.1M basic shares were pre-announced in January (#msg-127724589). TCON has a lot of balls in the air for a small biotech company.